RE:RE:RE:ONCY's pelareorep is now Phase 3-readyGiven that pelareorep has demonstrated single agent anti-cancer activity in a well controlled and randomized Phase 2 clinical study, multiple Big Pharma companies are seeing of the significantly positive results from this late-stage clinical study.
And late-stage biotech companies with novel biological cancer therapies are what Big Pharma are "paying up for", particularly now that the FTC is targeting deals over US$25 Billion and that we are moving into this second half of 2023 when M&A deals are ready to pick up for late-stage cancer assets under the US$25 Billion ceiling..